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Superior Chemotherapeutic Efficacy of Amphotericin B in
Thftsin-bearing Liposomes againstLeishmania Donovani
Infection in Hamsters
AJAY K. AGRAWAL*. A. AGRAWALt. A. PALt. P.Y. GURU and C.M. GUPTA
Ce"tral Drag Research I"stiwte. Lllck"ow 226001. I"diu
(Received2/ Jllly 2001: Revised 17 September 2oo/)
Chemotherapeutic efficacyof the amphotericin B (Amp B). which is the drug of choice for treatment of
the leishmanial infections (kala-azar) that become resistant to the conventional chemotherapy using
antimonials. has been examined in theLeishmania dOllovalliinfected hamsters after encapsulating the
drug in tuftsin-free as well as tuftsin-bearing liposomes. The activity was significantly increased
(p< 0.05) by delivering Amp B in tuftsin-free liposomes. This antileishmanial effect of the liposom-
ized Amp B was further increased (p < 0.05) by grafting the natural macrophage-activator
tetrapeptide, tuftsin (Thr-Lys-Pro-Arg). on the liposome's surface. This could possibly be attributed
to both the enhanced drug tolerance after liposomization as well as to the increased uptake of tuftsin-
bearing Amp B-laden liposomes by the macrophages. In addition to the increased efficacy,
encap~ulation of Amp B in the tuftsin-bearing liposomes also enhanced the drug accessibility to areas
(e.g. bone marrow) that are otherwise inaccessible to the free drug. These results further demonstrate
the usefulness of tuftsin-bearing liposomes as drug vehicles in treatment of the macrophage-based
infections that have been reviewed recently (Agrawal. A.K. and Gupta, C.M. (2000). Tuftsin-bearing
liposomes in treatment of macrophage-based infections,Adv. Drug Deliv. Rev.,41 135-146).
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The inherent tendency of "conventional" liposomes to
concentrate in the mononuclear phagocyte system (MPS)
has been exploited in enhancing the non-specific host
defense against a variety of infections, and also as carriers
of antibiotics in treatment of infections involving MPS
(Patel, 1992: Ten Hagenet al.,1998). As leishmania
parasites mainly reside within the mononuclear phago-
cytic cells. a number of successful studies have been
carried out by using liposomes as the antileishmanial drug
carriers in treatment of the disease (Cauchetieret al.,
2000; Frezardet af.. 2000).
However. effective management of the kala-azar has
proved to be difficult due to increasing resistance of the
parasite to conventional anti-Ieishmanial drugs, like anti-
monials, and also due to its high toxicity (Coukell and
Brogden. 1998: Yardley and Croft, 2000). Although the
c:
potent anti-fungal drug, Amp B is quite effective also as an
anti-Ieishmanial agent, it suffers from several side effects
including marked renal toxicity. The toxic effects of Amp
B can be significantly minimized, while keeping intact the
anti-Ieishmanial property, by encapsulating this' drug in
liposomes (Murray, 1999:Sundar 2001). The liposomized
Amp B besides being effective against theL. donovani
infections in the immunocompetent hosts has also been
s own to be quite effective in T-cell deficientcases, which
is quite unlike the other anti-Ieishmanial drugs, such as
pentavalent antimony and pentamidine (Murrayet al.,
1993). AmBisome (liposomal Amp B) was the first drug
approved for the treatment of visceral leishmaniasis by the
US FDA (Meyerhoff, 1999).As the host defense against
this intracellular leishmanial infection is T-cell-dependent,
kal -azar has predictably joined the list of AIDS-related
opportunistic infections in endemic areas (Murray, 1999)
and liposomal Amp B has also been shown to be quite
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effective in controlling the disease in such cases
(Lagunaet al.,1999; Borrelliet al.,2000; Mastroianni
et aI., 2000).
We have previously demonstrated that encapsulation of
stibanate in tuftsin-bearing liposomes markedly enhanced
the efficacy of the drug (at least 200 times) against
L donovaniinfections in hamsters (Guruet al.,1989).As
an extension of this study, we have now examined the
suitability of the tuftsin-bearing liposomes as Amp B
vehicles in treatment of theL. donoval/iinfections in
hamsters.
MATERIALS AND METHODS
All the materials used were of the analytical grade. Egg
phosphatidy1choline(egg PC) was isolated from egg yolk
(Agrawalet al.,1987). Cholesterol (CH) was obtained
from Centron Research Laboratory (Mumbai, India) and
was used after recrystalizing it three times from methanol.
Amp B as Fungizone. a lyophilized pharmaceutical
preparation in deoxycholate, was obtained from Sarabhai
Chemicals (Baroda, India) and was reconstituted in 5%
dextrose before use. Amicon Centriflo CF-25 was
purchased from Millipore (Watford UK). RPMI-1640
and reagents for cell culture were from Gibco (Grand
Island, USA).
Thftsin
Tuftsin was modified at the C-terminus (Thr-Lys-Pro-
Arg-NH-(CH2h-NH-COClsH31) to facilitate its incor-
poration in the liposomes bilayer. Both tuftsin and
modified tuftsin were prepared as described earlier
(Singhalet al., 1984).
Animals
Male golden hamsters(J'desocricetlls allratlls)were used
for in vivo evaluation of the liposomized Amp B
preparations, while BALB/C mice (weight 18-22g)
were used for isolating macrophages for the illvitro
experiments.
Parasites
The Leishmania dOl/ovanistrain (HOM/IN/80/Dd 8),
originally isolated from a kala-azar patient from
Bihar (India), was a kind gift from professor P.C.c.
Garnham, Imperial College, London. The strain is being
regularly maintainedil/ vitroas promastigotes in NNN
medium or in Leibovitz (L-15) medium supplemented
with 10%fetal trypto<;ephosphate broath (TPB) and 10%
fetal bovine serum (FBS). and as amastigotes in golden
hamsters.
Infection
In Vivo
Amastigotes were isolated from the spleen of infected
hamsters (> I month old infection). These were suspended
in Locke's solution (8.0g NaCl, 0.2 g KCI, 0.2 g CaCI2,
0.3 g KH2P04 and 2.5g glucose in II, pH 7.2) to give
about 10Kamastigotes/ml. One hundred microlitre of
this suspension (containing about 107 amastigotes) was
administered intracardiacly (Lc.) to each hamster (weight
40-45 g). The establishment of infection was assessed by
sacrificing 3-4 animals and measuring the parasites loads
in their spleens.
III Vitro
Peritoneal macrophages were obtained from BALB/C
mice 3-4 days after intraperitoneal injection of 2% starch
sulution (0.5 mI). The macrophages were harvested in
RPMI-I640 medium containing heparin. These were
washed twice and resuspended in complete RPMI-1640
medium supplemented with 10% fetal calf serum.
Gentamycin (40 J.Lglml)was added to the medium to
prevent bacterial growth. Cells were plated in multi
well slide Lab Tek Chambers (Miles, USA) and incubated
for 24h at 37°C. Non-adherent cells were removed by
thorough washing. The cells were routinely found to be
more than 95% viable by trypan blue exclusion test.
Promastigotes at a ratio of three parasites per macrophage
were used to infect the cultures. Infection was permitted to
proceed for 4 h at 37°C, after which all the extracelluar
organisms that failed to parasitize the macrophages were
removed by washing. In most instances 75-80% of the
m crophages were to be infected. The infected macro-
phages were incubated in the culture medium under 5%
C02 atmosphere for 24h prior to drug treatment.
Liposomes
Liposomes were prepared from egg phosphatidy1choline
and cholesterol (molar ratio 7:3) by probe sonication and
fractionated by centrifugation as described earlier
(Agrawalet al.,200I). Briefly, the lipids (total weight
45 mg), with or without tuftsin (7-8% by weight of PC),
were dissolved in chloroform in a round-bottomed flask
and to it Amp B (I mg) was added in methanol. The
organic solvents were removed under reduced pressure,
resulting in the formation of a thin lipid filmon the wall of
the flask.The dried lipid mixture was dispersed in 150mM
saline and sonicated for 30min under nitrogen atmosphere
using a probe-type sonicator. It was centrifuged at12,000g
for 30min at 4°C. The supernatant was dialyzed against
150m\1 saline to remove free Amp B, and the amount
of Amp B incorporated in liposomes was determined
spectrophotometrically (Mehtaet al.,1986).Circa 85% of
the Amp B was found to be associated with the liposomes.
The outer diameter of the liposomes, as determinedby
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el~ctron microscopy. was circa 80nm (Agrawal and
Gupta.2000b).
Treatment
In Vivo
Hamsters on day 15-18 post infection were divided into
four groups. each group consisting of a large number of
animals with 4-5 animals for each test dose. Animals in
Group-I and Group-II were given free Amp B and Amp B
in tuftsin-free liposomes (Lip-Amp B). respectively.while
Group III was given Amp B in tuftsin-bearing liposomes
(Tuft-Lip-Amp B). The Group IV was treated as controls
and was given saline only. The animals were sacrificed
15 days after the treatment. Their spleen impression
smears were prepared and stained with Giemsa to assess
the amastigote counts. Inhihition of the amastigote
number was calculated using the following equation:
PI 100- (NT jNC X 100)
where PI. percentage inhibition; NT. actual number of
amastigotes/IOOspleen cell nuclei after the treatment; NC.
mean number of amastigotesl100 spleen cell nuclei in
control animals on the corresponding day of the autopsyof
treatedanimals. .
In Htro (Treatment oj Injected Macrophages)
Pulse treatment was used in these experiments (Rabino-
vitchet al..1986). Infected macrophages were washed
once with the medium and placed in complete RPMI-I640
medium containing free Amp B. Lip-Amp B or Tuft-lip-
Amp B. The mixture was incubated for 3h at 37°C under
5% C02 atmosphere. It \vas washed and the complete
medium replaced with the fresh medium without any drug.
and then incubated for 20h in a C02 incubator. At the end
of this period. the cells were fixed in methanol and stained
with Giemsa.The number of amastigotes/100 macrophage
nuclei in drug treated and control cultures were
determined. The percent of leishmanicidal activity was
calculated according to the following equation:
PI 100- (NT jNC X 100)
where PI. percentage inhibition; NT. number of
amastigotes/IOOnuclei in treated group; NC. number of
amastigotes/IOOnuclei in control group.
RESULTS
The effect of tuftsin mediated liposome targeting to
macrophages on antileishmanial activity of Lip-Amp B
was assessed by evaluating the efficacies of Lip-Amp B
and Tuft-Lip-Amp B againstL. donovGniinfectionsin
vitro.We have previously demonstrated that Amp B
incorporatedin eggPC/CH appearedto be much more
effective as compared to that in SoyaPC/CH liposomes
(Ahmadet al..1991). Therefore. the former formulation
was used throughout the study. Table I shows that anti-
leishmanial activities of both free and liposomized Amp B
increased with increasing Amp B concentration in the
medium. While no problems were encountered by using
Amp B up to 10ILglmlconcentration in liposomes.
extensive cell lysis occurred when the drug was used at
this concentration in native form. The anti-leishmanial
activity of Lip-Amp B at all Amp B concentration was
higher than that observed with free Amp B in identical
conditions (Table I). This activity further increased when
tuftsin was grafted on the surface of Amp B containing
liposomes. The difference observed between the anti-
leishmanial activities of Lip-Amp Band Tuft-Lip-Amp B
was highly significant(p< 0.0 I) at Amp B concentra-
tions lower than 10ILglml.These results clearly indicate
that encapsulation of Amp B in liposomes helps not only
in reducing the drug toxicity but also in increasing the
drug efficacyagainstL. donovaniinfectionsinvitro.Thus.
to achieve 50% inhibition inL. dOllovanigrowth and
multiplication only 5 and 2.5 ILglml concentrations of
Amp B were required after its encapsulation in tuftsin-free
and tuftsin bearing liposomes. respectively.
To examine the validity of the above results underin
vivoconditions. we have evaluated the anti-Ieishmanial
activity of various Amp B preparations inL. dOllovani-
infected haJIlsters. The anti-Ieishmanial activity was
assessed by measuring the parasite load in spleens of
infected animals after their treatment with various
formulations of Amp B on day 15 post infection. The
results given in Table II indicate that the anti-Ieishmanial
activity of Lip-Amp B was significantly(p< 0.05)
greater than that observed with free Amp B. This
difference in the activity further increased(p< 0.01) by
grafting tuftsin on Lip-Amp B surface.
The tissue distribution experiments showed the higher
and faster uptake of Tuft-Lip-Amp B from the circulation
with most of the liposomes being cleared from the
circulation within I h after administration as compared to
Lip-Amp B. Moreover. the drug distribution in various
tissues was also influenced by the degree of infection and
TABLE 1 Enhanced effect of tuftsin-bearing Amp Bladen liposomes on
L d'J/lOt"llli infections in mouse macrophagesill vitro. (Value shown are
means of 3-4 experiments :t S.D) ,
Sample Amp B dose jLglml)
1.25
2.5
5
10
1.25
2.5
5
10
1.25
2.5
5
10
%inhibition of infection
Amp B 18.26 :t 1.92
29.61 :t 3.37
39.62 :t 3.99
Cell lysis
39.10:t 2.11
40.39 :t 8.36
51.89 :t 2.02
69.56 :t 1.24
46.19 :t 0.96
53.54 :t 3.76
61.40 :t 4.65
72.90 :t 3.84
lip-Amp B
Tuft-lip-Amp B
-.' -- ., ~..,. --;~ .---.--
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TABLE II Superior chemotherapeutic efficacy of tuftsin-bearing Amp
B. laden liposomes onL dOllovani infections in hamsters. (Each
experiment was carried out at least two times. Values are m.:ans of 3-5
animals (S.D)
Sample
Ampn
Amp B dose
(single: mglkg)
% inhibition of infection
in spleen
0.5 37.6 ~ 7.8
38.7 :: 7.0
38.5 ~ :!7.3
37.:! ~ 6.8
60.1 ~7.9
59.9 ~ 7.1
71.2 ~ 5.7
68.7~4.1
81.4~7.3
75.0 ~ 9.2
78.8 ~ 5.3
80.9 ~ 6.7
Lip-Amp B 0.5
Tuft-Up-Amp B 0.5
the drug concentration, and in the case of Tuft-Lip-Amp B
was maximum for all organs of infected animals except
kidney at I h, suggesting immediate uptake of these
liposomes by the macrophage-rich organs (liver, spleen
and lung). However, this was not the case with Lip-Amp
B, indicating that, mere liposomization of Amp B is not
enough to significantly alter its distribution in the
macrophage-rich organs of the infected animals (Agrawal
el al.;manuscript under preparation).
These results clearly demonstrate that the anti-
leishmanial activity of Lip-Amp B is significantly
increased by grafting the macrophage activator tetrapep-
tide, tuftsin, on the liposomes surface. Initial experiments
with multiple doses of free Amp B, Lip-Amp Band Tuft-
Lip-Amp B administered to the infected hamsters
produced significantly high degree of inhibition in spleen
forbothLip-AmpBand Tuft-Lip-AmpB,as comparedto
that treated with free Amp B only. However, under these
conditions, no statistical difference was seen between the
anti-Ieishmanail activities of Lip-Amp Band Tuft-Lip-
Amp B (Agrawalel al.:unpublished observations).
DISCUSSION
Leishmaniasis has re-emerged from near eradication. The
estimate for the incidence and prevalence of the disease
world-wide is 0.5 and 2.5 million per year, respectively.
Numerous efforts have been made towards the develop-
ment of effective vaccines against leishmaniasis. In spite
of promising results with Phase 3 trials with the first
generation vaccine (killed leishmania organism mixed
with low concentration of BCGas an adjuvent>,there is no
effective leishmania vaccine as yet on the horizon, and
chemotherapy remains the only practical way to combat
all fonns of the disease. The major front line drugs
available for leishmaniasis are toxic. Several doses need to
be given over a prolonged period of time and development
of drug resistance becoming a serious problem.
We have previously demonstrated that the efficacy of
Tuft-Lip-Amp B was markedly enhanced as compared to
Lip-Amp B against A.fwnigalusinfections in mice, both
in tenns of the survival times of animals and reduction of
fungal load, primarily due to macrophage activation by
tuftsin. Tuftsin incorporation in the Lip-Amp B did not
seem to affect the drug toxicity, as we observed almost
identical LD50value for both Lip-Amp Band Tuft-Lip-
Amp B (Owaisel al., 1993).
In our earlier biodistrihution study, we showed that
increase in the activity of Lip-Amp B against leish-
maniasis was related to the reduced drug toxicity rather
than altered drug distribution at the site of infection
(Ahmadel al.,1991). In the present study, we show that
uptake of Tuft-Lip-Amp B is higher and faster from the
circulation as compared to Lip-Amp B. Also, grafting of
tuftsin on Lip-Amp B alters significantly its distribution in
the macrophage-rich organs of infected animals. It may
thus be suggested that the higher efficacy of Tuft-Lip-
Amp B observed here could be due to both the increased
drug tolerance and enhanced uptake of liposomized drug
by the macrophage-rich organs of the infected mice.
Tuftsin-bearing liposomes also increase the drug accessi-
bility to areas like bone marrow which are otherwise
inaccessible to free Amp B, and are the main cause of
relapse of the leishmanial infection. The improvement in
the therapeutic efficacy of the Tuft-Lip-Amp B might have
resulted from the respiratory burst-inducing activity of
tuftsin (Singhel al., 1992), in addition to the effect of
targeted drug delivery of the drug to the macroph~ges.
In conclusion, the present study clearly shows that the
encapsulation of Amp B in liposomes significantly
enhances its anti-Ieishmanial activity, which is consistent
with other reports (Bodheel al.,1999; Mastroianniel al.,
2000). Also, it demonstrates that tuftsin-mediated
targeting of Amp B loaded liposomes to macrophages
further increases the drug efficacy. Moreov~r, as observed
in vilro, the difference between the anti-Ieishmanial
activities of Lip-Amp Band Tuft-Lip-Amp B (Table II)
was much more prominent at lower Amp B dose
(0.5mglkg), as compared to higher dose (1.0mglkg).
Besides, reducing the parasite load in the spleen, this
fonnulation was quite effective in eliminating the liver
and bone marrow parasite loads (Agrawalel l.;unpub-
lished observations). This could perhaps be attributed to
the higher uptake of Tuft-Lip-Amp B, as compared to
L p-Amp B, by the monocytes/macrophages (Singhal
l al.,1984), which in turn should help the MPS cells in
achieving an optimal intracellular drug concentration.
Multiple dc :s of Lip-Amp Band Tuft-Lip-Amp B to the
infected hamsters produced significantly high degree of
inhibition in spleen, as compared to that treated wilh free
Amp B only. However. no statistical difference was seen
betwc.:n the anti-Ieishmanail activities of Lip-Amp Band
Tuft-Lip-Amp B (Agrawalc'l al.; unpublished obser-
vations).This could possibly be attributed to the saturation
f tuftsin receptors on monocytes/macrophages due to its
high dose as tuftsin has been shown to have inhibitory
Journal of Drug Targeting.10,41-45 (2002)
effects at its high concentration (Babcocket al., 1983).
This study is in accordance with our previous study (Guru
et (/1..1989), which showed an increased anti-Ieishmanial
adivity of liposomized sodium stibogluconate after
grafting tut"tsin on the liposomes surface.
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